Efficacy and Safety of Intramuscular Midazolam Compared to Buccal Midazolam in Pediatric Seizures

• Status: Completed
• Trial end date: 2018-11-01
• Target enrollment: 0
• Participant gender: All

Summary

The goal of this study is to prove that intramuscular midazolam is more effective than buccal midazolam in cessation of seizure activity with comparable side effects.

• Phase: Phase 4
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Hamad Medical Corporation
• Treatments: Midazolam

Criteria

Inclusion Criteria:

• Children 6 month to 14 years who will be presented to the pediatric emergency or attended by emergency medical service who have active seizure and had no intravenous access would be eligible for the study.

Exclusion Criteria:

• Cardiac arrest

• Head trauma

• Drowning

• Congenital heart disease

• Inborn errors of metabolism

• Electrolyte imbalance (hypocalcaemia, hyponatremia and hypoglycemia)

• Hemodynamic instability

• Allergy to benzodiazepines

• Focal seizures with preserved level of consciousness